Columbia Labs
This article was originally published in The Tan Sheet
Executive Summary
Class action suit filed in summer 2000 alleging company made "materially misleading statements and omissions" about its nonoxynol-9 spermicide-containing Advantage-S and Rx progesterone gel fertility treatment Crinone dismissed May 9. Class action pertained to stockholders purchasing Columbia shares between Nov. 8, 1999 and June 9, 2000. Advantage-S was found to be ineffective at protecting against HIV in a UNAIDS Phase III trial conducted last year (1"The Tan Sheet" July 17, 2000, p. 8)